Table 1.
Characteristics of efavirenz participants by virologic failure status (Yes vs. No)
| Characteristics | Virologic failure (n = 98) |
No virologic failure (n = 698) |
p-Value for overall differences; Significance limit: p< 0.05 |
|---|---|---|---|
| Efavirenz Concentration Group, n (%) | |||
| Low¥ | 22 (19%) | 92 (81%) | 0.04 |
| Within | 65 (12%) | 493 (88%) | |
| High | 11 (9%) | 113 (91%) | |
| Assigned NRTIs, n (%) | |||
| TDF/FTC | 48 (12%) | 352 (88%) | 0.83 |
| ABC/3TC | 50 (13%) | 346 (87%) | |
| Sex, n (%) | |||
| Male | 83 (13%) | 570 (87%) | 0.57 |
| Median age, years (IQR) | 36 (29.8–43) | 38 (31–46) | 0.01 |
| Race/Ethnicity, n (%) | |||
| White, non-Hispanic | 31 (10%) | 283 (90%) | 0.03 |
| Black, non-Hispanic | 47 (17%) | 224 (83%) | |
| Hispanic | 18 (10%) | 166 (90%) | |
| Othera | 2 (8%) | 22 (92%)* | |
| Screening HIV-1 RNA, n (%) | |||
| ≥100,000 copies/mL | 44 (13%) | 296 (87%) | 0.66 |
| IV drug use, n (%) Never | 87 (12%) | 635 (88%) | 0.46 |
| Median weight, kg (IQR) € | 73.6 (65.6–86.3) | 76.4 (68.2–87.5) | 0.12 |
| Median weight, kg by Quartiles € Θ | |||
| Weight ≤ 1st Quartile | 62.36 | 62.05 | 0.74 |
| 1st Quartile < Weight ≤ Median | 72.27 | 71.82 | 0.96 |
| Median < Weight ≤ 3rd Quartile | 79.68 | 81.36 | 0.08 |
| Weight > 3rd Quartile | 95.50 | 97.50 | 0.30 |
NRTIs, nucleos[t]ide reverse transcriptase inhibitors; TDF/FTC, tenofovir disoproxil fumarate/emtricitabine; ABC/3TC, abacavir/lamivudine; IQR, interquartile range
11 Asian, 8 Native American/Alaskan Natives, 5 subjects reporting more than one race, and 3 subjects with missing race/ethnicity information
Low concentration group is combined with both concentration groups
Missing race/ethnicity values for three participants not included in the analysis (n = 25)
Missing weight values for nine participants not included in the analysis
Quartiles of the weight variable (kg rounded to the nearest whole number): 0% (40 kg), 25% (68 kg), 50% (76 kg), 75% (88 kg), 100% (172 kg)